Peter Attia interviews Jim Otvos, a physical chemist who developed NMR-based blood analysis that underpins advanced lipoprotein testing (LDL-P/HDL-P). Otvos recounts how a disputed 1980s New England Journal of Medicine cancer claim led his lab to identify reproducible NMR signals from lipoprotein particles, enabling rapid particle quantification and later subclass sizing. He argues that apparent risk from “small, dense” LDL is largely explained by higher LDL particle numbers at a given LDL-cholesterol level, warning against the common “large, fluffy LDL is safe” interpretation.
The discussion then centres on discordance between LDL-C and LDL-P, links to insulin resistance, and how NMR-derived composite scores such as LPIR and the Diabetes Risk Index may help identify metabolic risk earlier than glucose-based criteria. Otvos also describes “glyc”, an NMR-derived inflammation marker tied to glycosylated acute-phase proteins, which he says is more stable than CRP.
A major focus is MVX (metabolic vulnerability index), a composite score (including small HDL-P, glyc, citrate and branched-chain amino acids) that Otvos says strongly predicts all-cause mortality across cohorts, including claims of prediction in a young-adult cohort followed for decades. Finally, he gives an insider account of Liposcience’s acquisition by LabCorp, saying it halted plans to deploy FDA-cleared Vanta NMR analysers broadly and raising concerns about the ageing analyser fleet and long-term continuity of NMR testing.
Otvos says LabCorp’s NMR-derived “metabolic vulnerability index” (MVX) does not simply rise with ageing, despite age being the strongest overall predictor of death. He frames this as a central and counterintuitive finding behind MVX’s reported association with all-cause mortality in multiple cohorts.
Read this moment →Otvos explains that an NMR signal known as “glyc” reflects glycan components on multiple acute-phase proteins and is correlated with inflammatory markers such as IL‑6. He argues it is less day-to-day variable than high-sensitivity CRP and can add independent predictive value in risk models.
Read this moment →Asked about patients who argue that large, “buoyant” LDL particles make high LDL particle number less concerning, Otvos rejects the claim. He says analyses show LDL size does not add predictive value once LDL particle number is accounted for, and cites familial hypercholesterolaemia as an example where LDL particles can be large yet risk remains high.
Read this moment →Otvos claims the same NMR spectrum used for lipoprotein particle measures can be processed with machine learning to generate an “extended lipid panel” including ApoB without added analytic cost. He frames it as a way to deliver higher-value lipid risk information more efficiently than conventional chemistry assays.
Read this moment →Otvos says analyses using stored samples from the Diabetes Prevention Program (DPP) found the NMR-derived LPIR score predicted diabetes risk better than fasting insulin, and showed lifestyle intervention reduced LPIR more than metformin. He adds later that the work has not been published, attributing delays in part to the primary author’s recent death.
Read this moment →Otvos says Liposcience’s goal was to become an IVD supplier, placing “Vanta” NMR analysers in clinical laboratories so NMR assays could be run widely. He claims LabCorp’s 2014 acquisition shifted the strategy to keeping NMR capability proprietary, ending broader deployment and, he says, curtailing awareness-building for new assays.
Read this moment →